0001104659-25-065888.txt : 20250703 0001104659-25-065888.hdr.sgml : 20250703 20250703200007 ACCESSION NUMBER: 0001104659-25-065888 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250702 FILED AS OF DATE: 20250703 DATE AS OF CHANGE: 20250703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dambkowski Carl CENTRAL INDEX KEY: 0001983476 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41740 FILM NUMBER: 251106792 MAIL ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apogee Therapeutics, Inc. CENTRAL INDEX KEY: 0001974640 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 934958665 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 650-394-5230 MAIL ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Apogee Therapeutics, LLC DATE OF NAME CHANGE: 20230420 4 1 tm2519824-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2025-07-02 0 0001974640 Apogee Therapeutics, Inc. APGE 0001983476 Dambkowski Carl C/O APOGEE THERAPEUTICS, INC. 221 CRESCENT ST., BLDG. 17, STE. 102B WALTHAM MA 02453 0 1 0 0 Chief Medical Officer 1 Common Stock 2025-07-02 4 M 0 7365 22.86 A 249088 D Common Stock 2025-07-02 4 S 0 6409 44.77 D 242679 D Common Stock 2025-07-02 4 S 0 2935 45.49 D 239744 D Common Stock 2025-07-02 4 S 0 746 46.26 D 238998 D Stock Option (Right to Buy) 22.86 2025-07-02 4 M 0 7365 0.00 D 2033-12-18 Common Stock 7365 164010 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.14 to $46.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.16 to $46.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. /s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski 2025-07-03